Navigation Links
AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims

Kenney & McCafferty Represent Whistleblower Dr. Stefan Kruszewski

(PRWEB) April 28, 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and damages to settle allegations that the company defrauded Medicare, Medicaid and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic Seroquel (U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.). This is the largest settlement of off-label marketing claims brought under the False Claims Act to date that involved civil-only fines. The $520 million settlement resolves a qui tam lawsuit filed by whistleblower Dr. Stefan Kruszewski, one of two relators to file a case. Dr. Kruszewski was represented by Brian Kenney and Tavy Deming of the Kenney & McCafferty law firm, along with William Leonard of Obermayer, Rebmann, Maxwell & Hippel.

Seroquel, a potent atypical antipsychotic, was FDA-approved only for two narrow uses in adults, schizophrenia and manic episodes associated with bipolar I disorder, at the time that Dr. Kruszewski filed his complaint. Harvard-trained psychiatrist Dr. Kruszewski alleged, however, that AstraZeneca engaged in an egregious, long term off-label marketing scheme by specifically targeting children and the elderly when those uses were never properly tested or approved by the FDA and that AstraZeneca marketed the drug for a litany of off-label uses, including depression, anxiety, ADHD and insomnia.

Dr. Kruszewski's complaint further alleged that AstraZeneca arranged for clinical trials that embellished efficacy data and also downplayed the drug’s serious side effects. Dr. Kruszewski alleged that AstraZeneca used these studies to stifle physician concerns about the drug's serious treatment-emergent side effects, including type II diabetes, hyperglycemia, cardiovascular complications, heart attacks, stroke, and, in some cases, an increase in the risk of mortality.

“The manipulation and misuse of Seroquel scientific data to support AstraZeneca’s off-label marketing campaign was the most disturbing aspect of the case to me,” Dr. Kruszewski said. “There were strong indications from AstraZeneca’s earliest clinical trials that Seroquel increased the risk of diabetes and induced profound sedation out of proportion to its weak antipsychotic effects.”

Kruszewski added that “rather than properly warning doctors and the public, AstraZeneca intentionally covered up the evidence on diabetes and other serious side effects and used the sedative property of Seroquel as a selling point.” “In the elderly population, they basically marketed Seroquel as an expensive sleeping pill and put hundreds of thousands of patients at risk for serious medical complications, premature cardiovascular disease, pneumonias, and premature death.”

“This was a well thought out marketing campaign that operated on many levels,” stated Brian Kenney. “AstraZeneca orchestrated scientific studies, ghost written articles, and the payment of large fees to academic psychiatrists to act as ‘thought leaders’ to promote the drug off label. The success can be seen in the huge numbers the campaign generated with 4.9 billion in sales in 2009.” “It’s particularly disconcerting that AstraZeneca successfully co-opted large portions of psychiatric academic community,” added Mr. Kenney.

“From the outset of this case, Dr. Kruszewski was passionate about bringing to light AstraZeneca’s concealment of unfavorable Seroquel studies as well as the company’s’ improper use of what he deemed to be flawed scientific studies to promote the drug off label,” said Tavy Deming.

The U.S. Attorney's Office for the Eastern District of Pennsylvania conducted the federal investigation into AstraZeneca's Seroquel marketing practices under the direction of U.S. Attorney Michael Levy, Assistant U.S. Attorneys Virginia Gibson and Colin Cherico.

U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.

Call Tavy Deming or Brian P. Kenney at 610-940-0327 to arrange availability for the complete news release or other public material related to the case.

About Kenney & McCafferty, P.C. (

Kenney & McCafferty ("K&M") specializes in qui tam and tax whistleblower litigation. K&M represents whistleblowers nationwide and has recovered more than $4 billion for the government in False Claims Act and tax whistleblower cases. Recent K&M pharmaceutical False Claims Act settlements include Pfizer, Inc./Geodon; Eli Lilly/Zyprexa; and Cephalon, Inc./Actiq, Provigil and Gabitril..

Brian P. Kenney, Esq.
Tavy Deming, Esq.
Kenney & McCafferty, P.C.
3031C Walton Road, Suite 202
Plymouth Meeting, PA 19462


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Launches Caller First IVR Solutions with AstraZeneca
2. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
3. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
4. Kaiser Permanente Gives $5 Million to Childrens Healthcare of Atlanta
5. RadioShack Customers Donate $1.3 Million to LIVESTRONG
6. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
7. Human Rights Denied: Obama Leaves 75 Million Children Behind
8. NVHR: Administrations 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
9. State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans
10. Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict
11. Esperanza Health Center Receives $6.5 Million in Stimulus Funds
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... scholarships for people struggling with eating disorders as a result of the $20,000 ... annual event, held at Fox Run Golf Club in Eureka, will help individuals ...
(Date:11/25/2015)... ... 25, 2015 , ... "When I underwent breast reconstruction following ... uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my own ... BRA for added comfort and support. The bra is easier to put on ...
(Date:11/25/2015)... ... , ... An unlikely combination of recycled plastic shopping bags ... people to have a more dignified and comfortable night’s sleep. , Residents of ... plastic bags into sleeping mats for the homeless. The project, according to ...
(Date:11/25/2015)... ... 25, 2015 , ... Bcureful—a non-profit organization devoted to advancing ... public awareness of the disorder while helping to bring expert medical care and ... bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert H. ...
(Date:11/25/2015)... ... , ... Students and parents have something to be thankful for this Thanksgiving ... awards. California Casualty is proud to support the contest designed to utilize ... driving, the number one killer of young drivers. , Almost 1,000 entries of ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: